×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
A Comparison of Study Startup Regulations and Timelines in Several Major Emerging Markets and the Decision Process for Selection
Session Chair(s)
David Passov, MBA
SVP, Strategic Advisory Partner
PRA Health Sciences, United Kingdom
The panel will explore conventional definitions of emerging markets; critique advantages and challenges of conducting trials in these markets; and examine study startup regulations/timelines and the decision-making process for entering these markets.
Learning Objective : Describe what defines an emerging market; Discuss the advantages and challenges of conducting clinical trials in emerging markets; Explain how several major markets compare in study startup regulations, timelines, and the decision process for country selection.
Speaker(s)
Panelist
Ori Ben-Yehuda, MD, FACC
Cardiovascular Research Foundation, United States
Executive Director, Clinical Trials Center
Panelist
Robert A. Baughman, PharmD, PhD
MannKind Corporation, United States
Senior Vice President, Clinical Sciences
Panelist
Nancy Widener, MS
Bristol-Myers Squibb Company, United States
Executive Director, Clinical Science and Operations
Have an account?